AstraZeneca (AZN) Reports Selumetinib Phase 3 Missed Primary Endpoint in NSCLC (ARRY)
Tweet Send to a Friend
AstraZeneca (NYSE: AZN) announced results from the Phase III SELECT-1 trial of the MEK 1/2 inhibitor, selumetinib, in combination ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
